Scholar Rock Holding Corporation (SRRK) 

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery and development of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of latent myostatin that has completed the Phase 3 clinical trials for the treatment of spinal muscular atrophy; and SRK-181, which is in Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies. It is also developing a pipeline of novel product candidates with potential to transform the lives of patients suffering from a range of serious diseases, including neuromuscular disorders, cancer, and fibrosis. The company has a collaboration agreement with Gilead Sciences, Inc. to discover and develop specific inhibitors of transforming growth factor beta activation for the treatment of fibrotic diseases. Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts.

Show less

Over the last 12 months, insiders at Scholar Rock Holding Corporation have bought $45.09M and sold $2.43M worth of Scholar Rock Holding Corporation stock.

On average, over the past 5 years, insiders at Scholar Rock Holding Corporation have bought $23.78M and sold $2.36M worth of stock each year.

Highest buying activity among insiders over the last 12 months: Invus Public Equities, L.P. (10 percent owner) — $90.52M. AKKARAJU SRINIVAS () — $30M. Samsara BioCapital GP, LLC (10 percent owner) — $15M.

The last purchase of 2,189,781 shares for transaction amount of $15M was made by Samsara BioCapital GP, LLC (10 percent owner) on 2023‑10‑16.